Full text is available at the source.
Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota
New understanding and treatments for fatty liver disease by targeting gut bacteria
AI simplified
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a common metabolic condition associated with obesity.
- NAFLD encompasses a range of liver diseases, such as hepatic steatosis and non-alcoholic steatohepatitis.
- Gut microbiota is recognized as a significant factor in the development of NAFLD and may act as a 'metabolic organ.'
- The condition is linked to alterations in energy metabolism, insulin sensitivity, and the metabolism of bile acids and choline.
- Therapeutic approaches targeting gut microbiota, including probiotics and fecal microbiota transplantation, are being explored for NAFLD management.
AI simplified